Physician profile
Summer S Gregson
NPI 1629206321
$1,854.27
in general payments reported to CMS, 2019-2025
26 companies · $521 in 2025
The $521 reported for 2025 was more than what 75% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $401 · 2022: $13.97 · 2023: $456 · 2024: $462 · 2025: $521.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,439.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $418.40 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $287.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $184.94 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $156.79 | 2025 | Veozah |
| Glaxosmithkline, LLC. | $142.38 | 2023-2025 | Shingrix, Arexvy, Bexsero |
| Abbvie INC. | $83.46 | 2021-2023 | |
| Pfizer INC. | $71.38 | 2023-2024 | |
| Abbott Laboratories | $48.82 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $43.79 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $43.30 | 2021-2024 | Airsupra |
| Merck Sharp & Dohme LLC | $40.27 | 2023-2024 | Dificid, Gardasil 9, Vaxelis |
| Bayer Healthcare Pharmaceuticals INC. | $35.89 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.90 | 2021 | |
| Xeris Pharmaceuticals, INC. | $24.56 | 2025 | Gvoke Hypopen |
| Sanofi Pasteur INC. | $24.47 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $23.97 | 2023 | Nexplanon |
| Otsuka America Pharmaceutical, INC. | $22.73 | 2025 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $22.32 | 2021 | |
| Medtronic, INC. | $21.95 | 2025 | Intellis Adaptivestim |
| Dynavax Technologies Corporation | $20.60 | 2024 | Heplisav-B |
| Sanofi-Aventis U.S. LLC | $18.93 | 2021 | |
| Genentech USA, INC. | $18.47 | 2021 | |
| Amneal Pharmaceuticals LLC | $18.32 | 2021 | |
| Esperion Therapeutics, INC. | $17.35 | 2021 | |
| Dexcom, INC. | $16.72 | 2024 | Dexcom G6 Transmitter |
| Amgen INC. | $14.65 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Summer Gregson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.